Inflammatory Disease News and Research

RSS

Glucosamine not reduces knee cartilage deterioration among individuals with chronic knee pain

A short-term study found that oral glucosamine supplementation is not associated with a lessening of knee cartilage deterioration among individuals with chronic knee pain.

11 Mar 2014

Ambit to provide overview of quizartinib drug candidate at Barclays Global Healthcare Conference

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Barclays Global Healthcare Conference to be held at the Loews Miami Hotel in Miami Beach, FL, March 10-13, 2014.

4 Mar 2014

New system delivers anti-inflammatory drugs to immune cells gone out of control

Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts. Their findings were published online Feb. 23 in Nature Nanotechnology.

24 Feb 2014

Research sheds light on pathological mechanisms that trigger psoriasis lesions

Streptococcal antigens (Streptococcus pyogenes) might be directly involved in the pathological mechanisms that result in the appearance of psoriasis lesions.

21 Feb 2014

Guerbet: FDA approves manufacturing plant for Lipiodol (ethiodized oil) Injection

Guerbet (GBT), the contrast agent specialist for medical imaging, today announced that it had received approval from the U.S. Food and Drug Administration (FDA) for a new manufacturing plant for Lipiodol® (ethiodized oil) Injection, in Montreal, Canada.

20 Feb 2014

Researchers examine link between non-restorative sleep and widespread pain among older adults

Researchers in the U.K. report that non-restorative sleep is the strongest, independent predictor of widespread pain onset among adults over the age of 50. According to the study published in Arthritis & Rheumatology (formerly Arthritis & Rheumatism), a journal of the American College of Rheumatology (ACR), anxiety, memory impairment, and poor physical health among older adults may also increase the risk of developing widespread pain.

13 Feb 2014

pSivida announces financial results for second quarter 2014

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.

10 Feb 2014

IQWiG study finds no added benefit of teriflunomide

Teriflunomide (trade name: Aubagio) has been approved in Germany since August 2013 for adults with relapsing remitting multiple sclerosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).

8 Jan 2014

Death rates two times higher in postmenopausal women with anti-CCP and RA antibodies

New research shows mortality rates are two times higher in postmenopausal women with rheumatoid arthritis (RA) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Findings published in the American College of Rheumatology (ACR) journal Arthritis & Rheumatism, soon to be called Arthritis & Rheumatology, indicate the higher mortality rates persisted after adjusting for age, positive rheumatoid factor, positive antinuclear antibodies (ANA) and disease modifying anti-rheumatic drug (DMARD) use.

23 Dec 2013

UT Southwestern receives $10M grant to find effective treatments for alcoholic hepatitis

UT Southwestern Medical Center has launched the local arm of a national, multicenter study aimed at finding more effective treatments for alcoholic hepatitis, a disease of the liver that often leads to cirrhosis and death in severe cases.

19 Dec 2013

UCD Conway Institute researchers identify potential biomarker of idiopathic pulmonary ﬁbrosis

Researchers in UCD Conway Institute have identified a potential biomarker of rapidly progressive pulmonary fibrosis and pinpointed a defective molecular function as a potential therapeutic target.

18 Dec 2013

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.

18 Dec 2013

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Researchers have developed a new assay for rapid and sensitive detection of Chlamydia trachomatis, the most common sexually transmitted infection (STI) in humans.

12 Dec 2013

Scientists identify key factor for limiting inflammatory responses, particularly in skin

Sanford-Burnham scientists have identified the B and T Lymphocyte Attenuator (BTLA) inhibitory receptor as a key factor in limiting inflammatory responses, particularly in the skin. The study, published online today in Immunity, provides clarity on how T cells get fired up to protect against pathogens, and then cool down to restore immune homeostasis.

6 Dec 2013

New finding links obesity and high-fat, high-sugar diets with changes in inflammatory status

Scientists have moved a step closer to an "obesity drug" that may block the effects of diets high in sugar and fats. In a new research report published in the December 2013 issue of The FASEB Journal, scientists show that there is an abnormal amount of an inflammatory protein called PAR2 in the abdominal fat tissue of overweight and obese humans and rats.

3 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Smaller micropolitan areas of the U.S. have very few rheumatologists

A novel study published in the American College of Rheumatology journal, Arthritis & Rheumatism, shows that smaller micropolitan areas of the U.S.-those with less than 50,000 people-have very few or no practicing adult rheumatologist. In some of these areas, individuals have to travel more than 200 miles to reach the closest rheumatologist.

27 Nov 2013

Discovery could rev up body's immune response to infection, autoimmune diseases

UT Southwestern Medical Center researchers report that disrupting the light-dark cycle of mice increased their susceptibility to inflammatory disease, indicating that the production of a key immune cell is controlled by the body's circadian clock.

8 Nov 2013

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

6 Nov 2013

Disruption of brain signals contributes to increased pain sensitivity in fibromyalgia patients

New research indicates that a disruption of brain signals for reward and punishment contributes to increased pain sensitivity, known as hyperalgesia, in fibromyalgia patients. Results published in Arthritis & Rheumatism, a journal of the American College of Rheumatology, suggest that this altered brain processing might contribute to widespread pain and lack of response to opioid therapy in patients with fibromyalgia.

5 Nov 2013